Cell and Gene Therapy Cold Chain Logistics Market AI Adoption

Cell and Gene Therapy Cold Chain Logistics Market Size, Trends with Key Players

The global cell and gene therapy cold chain logistics market size is calculated at US$ 1.89 billion in 2024, grew to US$ 2.19 billion in 2025, and is projected to reach around US$ 8.06 billion by 2034. The market is expanding at a CAGR of 15.64% between 2025 and 2034.

Due to the growing production of cell and gene therapies, there is a rise in the demand for cell and gene therapy cold chain logistics. To leverage it, new collaborations among the companies are increasing. AI is also being used to enhance its workflow. Moreover, their demand in different regions is also increasing due to advanced logistics infrastructure and their growing investments. The companies are also contributing to the launch of new logistics platforms. Thus, this is promoting the market growth.

Key Takeaways

• Cell and gene therapy cold chain logistics sector pushed the market to USD 1.89 billion by 2024.
• Long-term projections show USD 8.06 billion valuation by 2034.
• Growth is expected at a steady CAGR of 15.64% in between 2025 to 2034.
• North America held approximately a 44% share in the global cell and gene therapy cold chain logistics market in 2024.
• Asia Pacific is expected to be the fastest-growing region from 2025-2034.
• By service type, the transportation segment held an approximate 48% share in the market in 2024.
• By service type, the monitoring & tracking solutions segment is expected to be the fastest growing at a notable CAGR during the forecast period.
• By therapy type, the gene therapies segment held approximately a 46% share in the market in 2024.
• By therapy type, the cell therapies segment is expected to be the fastest growing during the forecast period.
• By temperature range type, the cryogenic (−150°C to −196°C) segment held an approximate 52% share in the market in 2024.
• By temperature range type, the refrigerated (+2°C to +8°C) segment is expected to be the fastest growing during the forecast period.
• By end user, the pharmaceutical & biotechnology companies segment held an approximate 55% share in the global cell and gene therapy cold chain logistics market in 2024.
• By end user, the specialty logistics providers segment is expected to be the fastest growing during the forecast period.

Quick Facts Table

What is the Cell and Gene Therapy Cold Chain Logistics Market?

The Cell and Gene Therapy (CGT) Cold Chain Logistics Market refers to the specialized supply chain infrastructure and services required for transporting, storing, and distributing temperature-sensitive CGT products. These therapies, including autologous and allogeneic treatments, require stringent conditions ranging from controlled refrigerated (+2°C to +8°C) to ultra-low and cryogenic temperatures (−80°C to −196°C). With the rise in commercial approvals of CGTs, the demand for reliable cold chain logistics has surged, ensuring product integrity, patient safety, and regulatory compliance. The market is shaped by innovations in cryogenic storage, real-time monitoring, and specialized distribution networks tailored to personalized medicine.

What are the Major Market Trends?

Growing collaborations: Due to the growing use of CGT, there is a rise in the demand for cell and gene therapy cold chain logistics. This is increasing the collaboration among the companies and CDMOs to enhance their development. Similarly, the collaboration among the companies and logistics providers is also increasing.

For instance,

• In July 2025, a manufacturing collaboration was announced between ViroCell Biologics, which is a viral vector contract development and manufacturing organisation (“CDMO”), and AvenCell Therapeutics, Inc., which is a leading clinical-stage cell therapy company. An investigational CD19/CD20 dual-targeted cell therapy, which is AVC-203 for the treatment of autoimmune diseases and B-cell malignancies, will be manufactured by this collaboration.
• In September 2024, to offer completely merged logistics and manufacturing services to pharmaceutical and biotechnology companies, a collaboration between Cryoport, Inc. and SK Pharmteco was announced. The contract manufacturing of both cell and gene therapy and small molecule products of SK Pharmteco will be backed by Cryoport in this collaboration.

What is the Use of AI in the Market?

The use of AI in the cell and gene therapy cold chain logistics market is increasing as it helps in real-time monitoring. It detects the deviations and minimizes the chances of failures. The AI algorithms also help to analyze the weather conditions, which in turn reduces the delayed deliveries. It also helps in managing the scheduled pickups and inventories. It also enhances the quality and risk management as it helps in detecting the failure routes. It can also be used for document verification. Thus, this enhances the safe deliveries with reduced costs.

Market Dynamics

Driver

Growing Demand for Personalized Therapies

There is a rise in the demand for personalized therapies, which is increasing the use of cold chain logistics. Individual logistics are also being used to ensure the timely and temperature-controlled deliveries. At the same time, with the use of real-time tracking, the patient are able to monitor their therapies. They also consist of a chain of custody and identity, which helps in reducing the mix-up of the therapies. Thus, this drives the cell and gene therapy cold chain logistics market growth.

Restraint

Lack of Skilled Personnel

The proper handling of the cell and gene therapies is crucial during the manufacturing, packaging, delivery, and collection. The inappropriate documentation of these therapies can lead to identity mix-up, delivering them to the wrong patient. Moreover, the lack of expertise or a trained person can affect their integrity. Thus, the lack of skilled personnel can lead to delays or even product rejection.

Opportunity

Growing CGT Development

Due to the growing application of cell and gene therapies, there is a rise in their development and clinical trials. This increases the demand for cold chain logistics. Depending on the type of CGT developed, the use of specialized logistics solutions is increasing. This is enhancing their innovations, which can offer customized packaging and a wide range of temperature storage facilities. Similarly, cold chain logistics, which can provide real-time tracking and monitoring technologies, as well as customized or individual logistic solutions, are being developed. Thus, this enhances the cell and gene therapy cold chain logistics market growth.

For instance,

• In June 2025, a memorandum of understanding (MoU) was signed between EVA Pharma and Porton Advanced Solutions, which is a global leading cell and gene therapy CDMO service provider. The CAR T-cell therapy development and manufacturing capabilities at EVA Pharma’s facilities will be developed and solidified by this collaboration.

Segmental Insights

How the Transportation Segment Dominated the Market in 2024?

By service type, the transportation segment led the cell and gene therapy cold chain logistics market with approximately 48% share in 2024, due to its fast delivery. It also offered strict temperature controls, which are essential for the CGT. This, in turn, increased their use in clinical trials as well. Thus, this contributed to the market growth.

By service type, the monitoring & tracking solutions segment is expected to show the fastest growth rate during the predicted time. They are being used for the management of product integrity as they are temperature-sensitive.  They help in detecting the delays. Thus, they help in providing the CGT with well-maintained integrity and effectiveness.

What Made Gene Therapies the Dominant Segment in the Market in 2024?

By therapy type, the gene therapies segment held the largest share of approximately 46% in the cell and gene therapy cold chain logistics market in 2024, as they were highly temperature sensitive.  They also required a cryogenic temperature for their stability. Moreover, their growing development also contributed to the same. This increased the demand for cold chain logistics.

By therapy type, the cell therapies segment is expected to show the fastest growth rate during the upcoming years. There is a rise in the clinical trials of cell therapies. The personalized cell therapies are also being developed, and the use of immunotherapies is also increasing. This is growing the demand for the use of cold chain logistics.

Why Did the Cryogenic (−150°C to −196°C) Segment Dominate in the Market in 2024?

By temperature range type, the cryogenic (−150°C to −196°C) segment led the cell and gene therapy cold chain logistics market with approximately 52% share in 2024, as it helps in maintaining the stability and functionality of the therapies. They were mostly used for autologous cell therapies to prevent their degradation. They were also used for logistics transportation due to the regulatory compliance, which enhanced the market growth.

By temperature range type, the refrigerated (+2°C to +8°C) segment is expected to show the highest growth during the predicted time. Due to growing allogeneic therapies, the demand for cold chain logistics is increasing. Moreover, due to their easy handling and regulatory standards, their use is increasing. Additionally, their low cost is also enhancing their acceptance rates.

Which End User Segment Held the Dominating Share of the Market in 2024?

By end user, the pharmaceutical & biotechnology companies segment held the dominating share of approximately 55% in the global cell and gene therapy cold chain logistics market in 2024, driven by growing CGT production. The companies also reflected a growth in the R&D. This, in turn, increased the shipments of CGT products. Thus, the demand for cold chain logistics increased.

By end user, the specialty logistics providers segment is expected to show the highest growth during the upcoming years. These providers are offering customized logistics solutions with experts in CGT product handling. They also provide end-to-end solutions with regulatory support. Furthermore, advanced technologies to maintain the product's integrity are also provided by them.

Regional Insights

North America Driven by High CGT Approvals

North America dominated the cell and gene therapy cold chain logistics market share 44% in 2024. North America consisted of robust industries that contributed to the increased development of cell and gene therapies. Moreover, their approvals increased the use of cold chain logistics. This enhanced the market growth.

U.S. Market Trends

There is a rise in the development of cell and gene therapies in the U.S. industry. This, in turn, is raising the demand for the use of cold chain logistics. Additionally, the presence of advanced logistics infrastructure offers them a variety of options with improved delivery. Moreover, the growing government investments are promoting their development.

Canada Market Trends

Canada is experiencing a rise in the biotech clusters, which is increasing the development and innovations of CGT and regenerative medicines. The industries as well as the institutes are also focusing on their new research and development. This is leading to a growth in funding and collaboration. Thus, this is growing the use of cold chain logistics for timely deliveries.

Growing CGT Trials Boost Asia Pacific

Asia Pacific is expected to host the fastest-growing cell and gene therapy cold chain logistics market during the forecast period. Due to expanding industries, there is a rise in the development of cell and gene therapies. This is increasing their trials, enhancing the need for cold chain logistics. Therefore, to deal with this rapid expansion, the healthcare sector is investing in the cold chain infrastructure development. Thus, this is promoting the market growth.

Market Value Chain Analysis

R&D

To provide safe and effective delivery of temperature-sensitive and fragile therapeutics, the development of innovative thermal packaging, advanced cryopreservation techniques, smart tracking, and monitoring systems, along with the optimization of supply chain models, will be the focus for cell and gene therapy cold chain logistics R&D.

Key Players: Marken, Cryoport, QuickSTAT, World Courier, Biocair

Clinical Trials and Regulatory Approvals

The clinical trials and regulatory approvals of cell and gene therapy cold chain logistics include the validation of temperature control, real-time monitoring, and packaging solutions.

Key Players: Marken, Cryoport, World Courier, Biocair

Patient Support and Services

To offer personalized and end-to-end guidance to the patient with emotional counselling, dedicated case managers, and financial assistance programs for the navigation of time-sensitive and complex logistics for the treatment are included in the patient support and services of cell and gene therapy cold chain logistics.

Key Players: Marken, Cryoport, Cencora, TrakCel, and Vineti, Cardinal Health

Top Companies in the Market

• Cryoport, Inc.
• World Courier
• Marken
• Catalent Cell & Gene Therapy Logistics
• Lonza Bioscience Logistics
• Thermo Fisher Scientific
• BioLife Solutions
• TrakCel
• Brooks Life Sciences
• Be The Match BioTherapies
• QuickSTAT 
• DHL Life Sciences & Healthcare
• FedEx Custom Critical Healthcare Solutions
• United Parcel Service
• McKesson Specialty Health
• Aramex Life Science Logistics
• CryoStore Ltd. 
• Integra LifeSciences Cold Storage Solutions
• Peli BioThermal
• Savsu Technologies

What is the Latest Announcement by an Industry Leader in the Market?

In January 2025, after revealing the Cryoport Express® Cryogenic HV3 Shipping System ("HV3"), the CEO of Cryoport, Jerrell Shelton, stated that to meet the needs of their patients and clients, they are continuously evolving their solution and are committed to predicting industry challenges. The patient access to vital cell therapies in remote areas and smaller cities is being enhanced, with the introduction of Cryoport Express® Cryogenic HV3 Shipping System, which in turn will enhance the patient outcomes.

Recent Developments in the Market

• In August 2025, plans to launch an online logistics platform are being made by the Pharmaceuticals Export Promotion Council of India (Pharmexcil). This platform will focus on enhancing the service quality by providing integrated compliance management, real-time tracking, a feedback mechanism, route optimization, competitive pricing through bidding models, digital document exchange, and booking of value-added services such as warehousing and insurance.
• In February 2025, to revolutionize cold chain compliance in life sciences and pharmaceutical industries, a platform that will bring together academia, industry, social, and government bodies was launched by the National Accreditation Body for Cold Chain Management (NAB-CCM). The individuals/companies in the field of cold chain management will receive professional training, ethical practices, and structured education in this initiative.

Segments Covered in the Report

By Service Type

• Transportation
  • Cryogenic Shipping
  • Refrigerated Shipping (+2°C to +8°C)
  • Frozen Shipping (−20°C to −80°C)
• Packaging Solutions
  • Insulated Shippers
  • Cryogenic Containers
  • Smart Packaging with IoT Sensors
• Storage & Warehousing
  • Cryogenic Storage (−150°C to −196°C)
  • Frozen Storage (−20°C to −80°C)
  • Refrigerated Storage (+2°C to +8°C)
• Monitoring & Tracking Solutions
  • Real-Time Temperature Monitoring
  • GPS-enabled Tracking
  • Blockchain-enabled Chain-of-Custody

By Therapy Type

• Gene Therapies
  • Viral Vector-Based Gene Therapy
  • Non-Viral Gene Therapy
• Cell Therapies
  • CAR-T Therapies
  • TCR-T Therapies
  • NK Cell Therapies
  • Stem Cell Therapies

By Temperature Range

• Cryogenic (−150°C to −196°C)
  • LN2 Dry Shippers
  • Vapor Phase LN2 Storage
• Frozen (−20°C to −80°C)
• Refrigerated (+2°C to +8°C)

By End User

• Pharmaceutical & Biotechnology Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Clinical Research Organizations (CROs)
• Academic & Research Institutes
• Specialty Logistics Providers

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait